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Abstract
Background: The pathogenesis of Alzheimer’s disease is attributed to misfolding of Amyloid-b (Ab) peptides. Ab is
generated during amyloidogenic processing of Ab-precursor protein (APP). Another characteristic of the AD brain is
increased phosphorylation of APP amino acid Tyr
682. Tyr
682 is part of the Y
682ENPTY
687 motif, a docking site for interaction
with cytosolic proteins that regulate APP metabolism and signaling. For example, normal Ab generation and secretion are
dependent upon Tyr
682 in vitro. However, physiological functions of Tyr
682 are unknown.
Methodology/Principal Findings: To this end, we have generated an APP Y682G knock-in (KI) mouse to help dissect the
role of APP Tyr
682in vivo. We have analyzed proteolytic products from both the amyloidogenic and non-amyloidogenic
processing of APP and measure a profound shift towards non-amyloidogenic processing in APP KI mice. In addition, we
demonstrate the essential nature of amino acid Tyr
682 for the APP/Fe65 interaction in vivo.
Conclusions/Significance: Together, these observations point to an essential role of APP intracellular domain for normal
APP processing and function in vivo, and provide rationale for further studies into physiological functions associated with
this important phosphorylation site.
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Introduction
The most common form of dementia in the world is Alzheimer’s
disease (AD), affecting about 1% of the human population by aged
65, and rising to 35–40% after age 85. Evidence points to a key
role for misfolded amyloidogenic Ab peptides in the pathogenesis
of AD (amyloid cascade hypothesis). The accumulation of Ab as
plaques in the hippocampus and other brain regions is a key
characteristic of AD pathology [1,2].
Ab peptides are generated during amyloidogenic processing of
Ab-precursor protein (APP). When APP is cleaved by b-secretase,
the soluble ectodomain (sAPPb) is released extracellularly whilst
the 99 amino acid C-terminal fragment (C99) remains membrane
bound. In a second proteolytic event, C99 is cleaved by the c-
secretase. Two peptides are released, Ab peptide consisting of
either 40 or 42 amino acids (Ab40 and Ab42, respectively) and an
intracellular product (AID or AICD), which regulates apoptosis [3]
and transcription [4]. An alternative, non-amyloidogenic pathway
also exists. In this pathway APP is cleaved by a-secretase in the Ab
sequence producing the soluble ectodomain (sAPPa) and the
membrane bound 83 amino acid C-terminal fragment (C83). C83
is also further cleaved by the c-secretase into the P3 and AID
peptides.
The degree to which APP function plays a role in the
pathogenesis of AD is unclear but changes in the apoptotic and
axonal activities of APP may underlie some aspects of AD
pathology [5,6]. However, until the in vivo functions of APP are
better understood this will remain a crucial question. APP null
mice have retarded neuron development, reduced hippocampal
neuron viability, diminished grip strength, locomotor activity and
postnatal growth [7], but can be normalized by over expression of
the sAPP-a ectodomain [8]. However, since the essential functions
of APP are compensated for by homologues APLP1 and APLP2,
the physiological significance of the short intracellular C-terminal
domain remains relatively unexplored in vivo.
The ,50 amino acids long APP intracellular region contains
seven residues that can be phosphorylated andseveral of these
amino acids are hyperphosphorylated in human AD brain.
However,it remains unclear whether this is a cause or a
consequence of neurodegeneration. One of these sites of particular
functional significance is Tyr
682, the phosphorylation of which is
increased in AD patients [9], especially in vasculature tissue of the
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evolutionarily conserved, canonical endocytic Y
682ENPTY
687
motif. Compromised endocytosis of APP is shown to significantly
decrease amyloidogenic processing and Ab secretion [11]. This
motif is also a docking site for cytosolic proteins, such as Fe65, that
regulate APP metabolism and signaling [12]. Phosphorylation of
Tyr
682 promotes interaction of Src-Homology 2 domain (SH2)
while it reduces interaction with a subset of proteins containing a
Phospho-Tyrosine-Binding (PTB) domain in vitro [13,14]. The
potential role of Tyr
682 phosphorylation state as a ‘‘biochemical
switch’’ to change the molecular composition of APP complexes is
an intriguing possibility. In the AD brain, a possible pathological
role for augmented APP phosphorylation on Tyr
682 needs further
exploration. To begin to specifically dissect the functional role of
APP intracellular domain in vivo we have generated APP KI mice
with a mutation in amino acid Tyr
682. Here we describe the
generation and initial characterization of APP KI mouse with
mutation of Tyr
682mutation of Tyr
682.
Materials and Methods
Ethics Statement
Mice were handled according to the Ethical Guidelines for
Treatment of Laboratory Animals of Albert Einstein College of
Medicine. The procedures were described and approved in animal
protocol number 20040707
Generation of APP Y682G and T668A mutant Mice
A 7.0-Kb genomic fragment containing exon 16 from C57BL/6
BAC DNA (RP23-99P18) was amplified by PCR with the
following primers:
Fwd: 59-aaaaGGTACCagtatctcttgtcctcacaatg-39;
Rev: 59-aaaaCCGCGGtaggtcccaaggcta-39.
This fragment flanked by KpnI and SacII sites was cloned into
pBS (pBS-EX16), and used as a template for subsequent cloning.
Two nucleotide mutations were introduced into pBS-EX16 vector
by site directed mutagenesis PCR. Firstly a SmaI/XmaI restriction
site (CCC GGA R CCC GGG) was created right in front of exon
16 by using the following primers:
Fwd: 59-ctattttaaacccggatctctgtacctgctttc-39;
Rev: 59-gaaagcaggtacagagatccgggtttaaaatag-39.
This new restriction site was used to verify the targeted clone.
Furthermore the nucleotide change from either ACC to GCC or
TAT to GGA in exon 16 generated the corresponding amino acid
mutation T668A or Y682G, respectively. The following primers
were used for this mutation: for T66A mutation,
Fwd, 59- TCGACGCCGCCGTGGCCCCAGAGGAGCGC-
CATCT -39;
Rev, 59- AGATGGCGCTCCTCTGGGGCCACGGCGGC-
GTCGA -39;
And for Y682G mutation,
Fwd, 59-tgcagcagaacggaggagagaatccaact -39;
Rev, 59- agttggattctctcctccgttctgctgca-39.
The 1.3 Kb Hind III-Sal I left arm and 2.4 Kb NotI-SacII right
arm were amplified from above mutated pBS-Ex16 by using the
following primers. For right arm:
Fwd, 59- aaaaaaagcttcaatggccatgaagga - 39;
Rev, 59-aaaaagtcgaccaggtatctgctgccat-39;
For left arm:
Fwd, 59- aaaaagcggccgcggccccacaaagcggagt -39;
Rev, 59- aaaaaccgcggtggcgcatgctgcag- 39.
The left arm contains SmaI/XmaI and either T668A or Y682G
mutations. Subsequently, the left arm and right arm were inserted
into a Soriano PGK-Neo-dTA vector. The resulting construct was
thus:
--- dTA cassette-Left Arm-LoxP1-PGK-Neomycin cassette-
LoxP2-Right Arm ---
The resulting construct was linearized with KpnI and purified
prior to injection in ES cells strain 129 by electroporation. ES
culture was performed on feeder layer, and further electroporation
and handling was also performed according to the methodology
employed at Dept of Cell Biology, Albert Einstein College of
Medicine, and according to Wakayama et al. In particular, after
electroporation, ES cells were re-plated in 55 cm
2 dishes and
grown until visible clones appeared. Clones were then picked and
transferred to 96 well plates in triplicates. Triplicates were either
screened by PCR or frozen for subsequent use and further
analysis.
Homologous recombinants were selected with G418 (200 mg/
ml) and dTA exclusion. Injection of the two Y682G mutant
targeted ES cell clones into C57BL/6J blastocysts was performed
at the Albert Einstein College of Medicine gene-targeting facility,
according to the facility protocol.
PCR Analysis
The PCR screening was performed using the Expand Long
Template PCR System (Roche-applied-Science) with Betaine,
according to the manufacturer instructions. PCR analysis of
recombinant ES cells and mice was conducted with the following
primers and digestion strategies to identify the correct recombi-
nant clones and strains:
ES cells:
Left arm:
Genomic primer: 59-CAGAAGGAAATGTCCCAGGA-39
Neo cassette primer: 59-CTTCTAGTTGCCAGCCATCTG-
39
Product: 1687 bp
Right arm:
Genomic primer: 59-GGATCTCACCCTGTTTTCCA-39
Neo cassette primer: 59- TGCACGAGACTAGTGAGAC-
GTG-39
Product: 3306 bp
Amplification of the right arm and digestion:
Genomic upstream primer: 59-CTACAGAGATAAATGTAC-
TTCG-39
Genomic downstream primer: 59-GGATCTCACCCTGT-
TTTCCA-39
Product: 3200 bp =wild type without SmaI/XmaI restriction
siteR3200 bp
Product: 3200 bp = mutant alle with SmaI/XmaI restriction
site; SmaI digestionR2800 bp +400 bp
Mice genotyping:
Fw primer: 59-ATGGCACCACCCACAATAGG-39
Rev primer: 59-CCTAGCAACTGGTAACAGTGC-39
Product: 2027 bp with Neo cassette
Product: 332 bp without Neo cassette
Product: 194 bp wild type
PCR products were digested to ascertain that the targeted
sequence was correctly inserted in the genomic DNA.
Southern Blot Analysis
Twenty mg of genomic DNA was digested with BamHI
overnight, run on a 1% TAE agarose gel and transferred on a
Hybond-N+ membrane (Amersham).
The probe was prepared by PCR from a BAC clone (RP23-
99P18) with the following primers:
-Left arm:
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Rev: 59-GGAGTAATTCAGGTGGAG -39
Probe size: 232 bp
-Right arm:
Fw: 59-actgggtggaaacacctgag-39
Rev: 59-gagagaggagcctgcagaga-39
Probe size: 542 bp.
One mg of PCR probe was labelled with 5 mL of 32P-dCTP
(3000 Ci/mmol, ICN) and purified through a Push Column
(Stratagene) according to the manufacturer’s protocol. Mem-
branes, containing the cleaved genomic DNA, were hybridized at
65uC and subsequently washed 4 times in SSC buffer (Sigma).
Film was exposed to the hybridised membranes at 280uC and
then developed.
Immunoblot analysis
Whole mouse brain was dounce homogenized (1:10 w/v) in
tissue homogenization buffer (20 mM Tris-base pH 7.4, 250 mM
sucrose, 1 mM EDTA, 1 mM EGTA plus protease (Roche,
Complete) and phosphatase inhibitors. For detection of full length
APP or APP CTF’s, the lysates were spun at 1,000 g for 15 min
and an equal amount whole protein homogenates were loaded for
either 4–20% SDS-PAGE or 13% tris-tricine SDS-PAGE
respectively and transferred onto nitrocellulose membranes for
detection using AbD (Zymed). For detection of sAPPa and b (IBL
antibody #27724 & #27722, respectively) an additional 45 min
spin at 100,000 g was used to remove membranes prior to SDS-
PAGE. Finally, in order enhance the signal for detection of both
sAPPb and APP CTF’s, the nitrocellulose membranes were subject
to epitope retrieval, prior to blocking, through incubation with
boiling PBS-T and subsequent cooling to room temperature.
Reverse Transcriptase-PCR and Real Time Quantitative
PCR Analysis
Mouse brain mRNA was extracted with Trizol reagent
(Invitrogen). Briefly, one mouse hemisphere was shock frozen,
weighed and homogenized in 4 volumes of Trizol reagent with an
electric dounce homogenizer, 3630’’ in ice. The suspension was
cleared of debris and membranes by centrifugation, and nucleic
acids were separated by chloroform extraction and ethanol
precipitation. The mix was applied to RNeasy columns, and
RNA purified with RNeasy Protect Kit (Qiagen) according to the
manufacturers’ protocols, including on-column DNase digestion
(Qiagen). One mg of RNA, quantified with the Nanodrop (Thermo
Scientific), was reverse-transcribed to cDNA using random
primers and the SuperScript III First-Strand Synthesis System
for RT-PCR kit (Invitrogen). Real time PCR was based on the
TaqMan technology, using 200 ng of cDNA and mouse APP, Beta
Actin and beta-2-microglobulin inventoried assays
(Mm01344172_m1, Mm00607939_s1 and m00437762_m1, Ap-
plied Biosystems) according to the manufacturer’s protocols, in
20 mL volume and in 96well plate format. The threshold cycles
(Ct) for the endogenous controls mRNA (b-actin and b-2-
microglobulin) and the target (APP) signal were determined and
the relative RNA quantification was calculated using the
comparative DDCt method. Each experiment was conducted in
triplicate. Data analysis was conducted according to Applied
Biosystems references and protocols, and using student-t test.
Neuronal cultures
Neuronal cultures were performed as described previously
[15,16] from E16-17 fetuses.
Mouse Dermal Fibroblasts
To culture mouse dermal fibroblasts (MDFs), skin was removed
from mouse tails, soaked in 70% ethanol, washed in PBS, diced
into small pieces and incubated at 37uC overnight in CO2
incubator in DMEM containing 20% FBS, supplemented with
penicillin/streptomycin and 1.6 mg/ml collagenase II. On the
next day, clumps were removed by passing through a nylon mesh,
and the material was centrifuged at 1000 rpm for 5 min to collect
the cells. The collected cells were maintained in DMEM
containing 20% FBS and penicillin/streptomycin.
Biotinylation and streptavidin precipitation
For biotinylation experiments, MDFs were washed three times
with cold PBS plus Ca
++ and Mg
++ (PBS-CM) and labelled for
30 min on ice in 0.5 mg/ml sulfo-NHS-SS-biotin (Pierce)
dissolved in PBS-CM. Free biotinylation reagent was removed
by washing three times with PBS-CM containing 0.1% BSA. The
cells were lysed in the RIPA buffer. The lysates were cleared by
centrifuging at 20,000 g for 10 min, and were mixed with
streptavidin agarose beads (Sigma S1638). After collecting
unbound lysate, the beads were washed four times with the RIPA
buffer, and were boiled in 26SDS buffer. Comparable volume of
the samples were subjected to western blot.
Synaptosomes
For synaptosomes, mouse brain was homogenized in H buffer
[5 mM Hepes/NaOH pH 7.4, 1 mM EDTA, 1 mM EGTA,
0.32 M sucrose, plus protease (PI) and phosphatase (PhI)
inhibitors] at 10% (w/v) and centrifuged at 800 g for 10 min.
The supernatant (S1) was separated to supernatant (S2) and pellet
(P2) by spinning at 9,200 g for 15 min. P2 was lysed on ice for
30 min in H buffer containing 35.6 mM sucrose. The lysed P2 was
separated to supernatant (LS1) and pellet (LP1) by spinning at
25,000 g for 20 min. S2 was separated to supernatants (S3) and
pellet (P3) by spinning at 165,000 g for 2 hrs, respectively. P3 was
suspended in H buffer containing 0.32 M sucrose by sonication.
Synaptosomes fractions represent: S1, postnuclear supernatant;
S2, cytosol, soluble proteins and light membrane; P2, crude
synaptosomal fraction; S3, soluble fraction; P3, light membrane
abundant in Golgi and ER; LS1, crude synaptic soluble; LP1,
synaptic membrane fraction.
Ab40 ELISA
DEA extraction of Ab from brain lysates was carried out as
previously described [17]. Prior to ELISA, DEA extracts were
further purified with Oasis HLB sample extraction cartridges
(Waters, WAT094226) to decrease background artifacts which
otherwise prevent detection of endogenous wild-type Ab40 in mice
[18]. Ab40 ELISA kit (IBL America, discontinued product) was
used according to manufacturer’s protocol with equal quantities of
protein loaded.
Co-immunoprecipitation
Whole mouse brain lysate was centrifuged at 9000 g for 15 min
and the resulting supernatant at 100,000 g for 45 min. The
supernatant was removed and the membrane pellet re-suspended
overnight in IP buffer (20 mM Hepes pH 8.0, 10% glycerol,
137 mM NaCl, 0.5% Triton-X-100, 2 mM EDTA) Any remain-
ing debris was removed with centrifugation at 9000 g for 15 min
and the membrane enriched supernatant diluted to 1 mg/ml in IP
buffer. 500 ug of membrane protein was used for each IP.
Supernatants were pre-cleared with 30 ul protein A/G (Pierce) for
30 min. 2 mg of either monoclonal anti-APP, non-specific mouse
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polyclonal control were added for incubation for 30 min. 20 ul
protein A/G was then added for overnight incubation. Superna-
tant was removed and the beads were washed 46with IP buffer.
Beads were re-suspended in 16LDS buffer with 10% BME and
1% NEM and incubated for 5 min at 95uC. Immunoblot analysis
was carried out as described above with a-APP IP probed for Fe65
and a-Fe65 IP probed for full length APP (22C11 antibody,
Millipore, 1:1500).
Pathological evaluation
Complete necropsy was performed on all mice and tissues
collected were fixed in Tellyesniczky/Fekete fixative (100 ml 70%
ethanol, 5 ml 37–40% formalin, 5 ml glacial acetic acid).
Appropriate tissues were decalcified using 10% formic acid
(Formical-2000H, Decal Chemical Corporation, Tallman, NY) or
3% hydrochloric acid (Cal-ExH, Fisher Scientific, Fairlawn, NJ) for
24 hours. Tissues were paraffin embedded and stained with
hematoxylin and eosin (H&E). A board certified veterinary
pathologist with no knowledge of the genotypes analyzed the
slides.
Results
Generation of APP Y682G and T668A Mutant Mice
The targeting strategy for the generation of the APP KI mice
entailed the replacement of APP exon 16 with exon 16 carrying
the Y682G or T668A mutation (Fig. 1A). The vector used the
floxed PGK-neo selection cassette and contains a 59 homologous
region and the negative selection cassette, PGK-dta. The 39
homologous region introduced the T668A or Y682G mutation,
BamHI and SmaI sites into the APP mouse gene. The linearized
targeting vector was transfected into 129 ES cells. In the presence
of the positive selection drug, G418, clones only survived if both
the PGK-neo selection cassette was integrated and the PGK-dta
cassette was removed by homologous recombination. ES cell
clones carrying the targeting vector by random, non-homologous
integration, were eliminated due to expression of diphtheria toxin.
After selection, ES cell clones carrying the proper homologous
recombination and the Y682G or T668A mutant allele were
identified by PCR for 39 region (i.e. right Arm: if homologous
recombination had occurred these primers would amplify a
product of 3.2 Kb). Out of ,600 screened ES clones, we found
two targeted clones for T668A and four clones for Y682G
mutation (Fig. 1B). Also, PCR amplification and digestion was
used to check the proper insertion of the construct in the genomic
DNA and the removal of the Neo cassette (not shown).
The occurrence of homologous recombination was confirmed
by both sequencing and Southern blot analysis (Fig. 1C). DNA
derived from individual Y682G or T668A ES clones was digested
with BamHI, gel separated, blotted into a nylon membrane and
hybridized with the 39probe. The 39 probe hybridizes with a
,7.5 Kb fragment derived from the wild-type locus. Homologous
recombination at the 39 homologous region yields a ,6.0 Kb
fragment upon BamHI digestion due to the introduction of the
BamHI site and the PGK-neo selection cassette. ES clones (T668A
or Y682G) carry a wild type allele (7.5 Kb) and a recombined
allele (6.0 Kb). The 7.5 Kb and 6.0 Kb bands had a similar
intensityproving the ES cells selected were clonal populations.
Similar results were obtained when homologous recombination at
the 59 site was assessed.
Two ES cell clones each for Y682G or T668A (129, agouti coat
color), carrying the correct site-specific homologous recombina-
tion, were injected into C57BL/6J blastocysts (black coat color).
The resulting chimeras with a high proportion of agouti coat color
(i.e. with a high relative contribution from the injected ES cells)
were backcrossed to C57BL/6J mice to obtain heterozygous
Y682G/wt, which were identified by PCR and Southern analysis
as described above (not shown) using tail DNA. Heterozygous
mice were crossed to Meu40-Cre mice to obtain Meu40/APP
Y682G/wt or Meu40/APP T668A/wt animals. Cre is a
bacteriophage P1-encoded recombinase that catalyzes site-specific
recombination between two 34 bp loxP recognition sites, resulting
in the excision of the intervening DNA sequences. The resulting
mice are named APP Y682G or APP T668A and are abbreviated
to APP YG or TA respectively, where appropriate.
Reduced b-cleavage and enhanced a-processing of APP
Y682G mutant mice
Previous studies have shown an important role for Tyr
682 in
shifting APP toward the amyloidogenic (b-processing) rather than
the non-amyloidogenic (a-processing) pathway in vitro [11]. Using
the models described above we established whether this is true in
vivo. Rates of a and b processing are reflected by the relative
abundance of the products of these two pathways, sAPP-a and
sAPP-b, respectively. Using immunoblot analysis an approximate-
ly 15-fold increase in sAPP-a in conjunction with a 3.5 fold
decrease in sAPP-b was detected in brain tissue from APP
YG/YG
mice compared to APP
wt/wt controls (Fig. 2A & 2B). Importantly,
no differences in sAPP-a and sAPP-b between APP
TA/TA, APP
TA/
wt and APP
wt/wt mice (Fig. 2C) was detected thus demonstrating
the highly specific role of Tyr
682 in modulating entry of APP into
the amyloidogenic pathway in vivo.
An analysis of APP COOH-terminal fragments (Fig. 2D) shows
that C83, which is formed in conjunction with sAPP-a, is greatly
increased in APP
YG/YG mice over APP
wt/wt control, consistent
with an increase in non-amyloidogenic processing. The level of
C99, which is formed in conjunction with sAPP-b, does not
change appreciably. Interestingly, the level of the phosphorylated
APP COOH-terminal fragments, p-C99, p-C89 and p-C83, were
unchanged in APP
YG/YG but, consistent with observations by
Sano, Y. et al. [20], were below detectable levels in APP
TA/TA
mice. This indicates that the steady-state phosphorylation of APP
is predominantly located on Thr
668 in the brain and that
phosphorylation of Tyr
682 is highly regulated (perhaps by signaling
mechanisms) and may have a short half-life. Also, it shows that the
Y to G mutation has not grossly altered the structure of the APP
intracellular domain that since the mutant APPYG protein still
undergoes other phosphorylation events. Other products of the
amyloidogenic pathway are Ab40 & 42. Only Ab40 was detectable
and showed a significant 25% decrease in APP
YG/YG mice
compared to APP
wt/wt controls (Fig. 2E), which was also consistent
with a decreased b-processing of APP. The change was specific for
the Y682G mutation since Ab40 levels were not changed in the
APP
TA/TA mice, again in agreement with previous findings [20].
Total APP levels show a 64% increase in APP
YG/YG over controls,
after normalization with Tubulin (Fig. 2A & B). Whether this
indicates an increased total half-life of APP Y682G as compared to
WT APP remains to be determined. It is also possible that
manipulation of the APP gene locus may have altered the
transcription/splicing of the mutant allele. To test for this, we have
now performed real-time RT-PCR and the data demonstrate that
expression levels of APP mRNA are not affected by the genetic
strategy used to do the KI (Fig. 3A). Thus any alterations in APP
protein and in its metabolites almost certainly reflect an effect of
the YG mutation on the fate of the APP protein, since it is very
unlikely that the point mutation will affect the translational
efficiency of the KI mRNA. Moreover, this increase in total APP is
APP Processing and Tyrosine
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YG mice. A, Schematic representation of the construct injected in 129 ES cells, showing site of APP T668A and Y682G
mutation on last Exon 16, primer sites, site of Southern Blot probe, LoxP, pgk-dta and pgk-Neo sites. The bottom graphics depict the construct with
and without the pgk-Neo cassette that has been removed by means of Cre recombinase. B, The right arm (p1–p2) PCR analysis of six positively
targeted ES clones. A 3.2 Kb PCR product digested by a novel restriction site Sma I produce 0.4 Kb and 2.8 Kb fragment. C, Southern Blot showing a
shift from the 7.5 Kb of the wild type genome to the 6.0 Kb band of two T668A and four Y682G positively knock in ES clones for the homologous
recombination of the mutated allele, due to the insertion of a new BamHI site.
doi:10.1371/journal.pone.0015503.g001
Figure 2. Altered APP proteolytic processing in APP
YG/YG mouse brain. APP
2/2 brain was used as a negative control in each experiment. A,
Immunoblot analysis comparing full length APP (WH = whole homogenates), sAPP-a, sAPP-b and tubulin levels between APP
wt/wt APP
YG/YG mice
(n=3). B, Quantitative analysis of panel A normalized to tubulin (*** =p ,0.01). C, WB analysis of APP
wt/wt, APP
wt/TA, APP
TA/TA, APP
wt/YG and APP
YG/YG
brain lysate showing full length APP, sAPP-a and sAPP-b. D, WB analysis of APP CTF’s using a tris-tricine gel, and comparing APP
wt/wt with APP
TA/TA
and APP
YG/YG. Five specific species representing C83, C89, C99 and their respective phosphorylated forms can be identified, noting that p-C83 and
C89 overlap. Bands at the very top and bottom are non-specific. E,A b4ELISA comparing APP
wt/wt with APP
TA/TA (n=3) and APP
wt/wt with APP
YG/YG
(n=4). APP
2/2 mice were also used to validate specificity of the assay (data not shown).
doi:10.1371/journal.pone.0015503.g002
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strains in the experiments shown in Fig 2C, Fig. 4 and Fig. 5). The
reason for this variability is not presently understood.
Since a- and b-cleavages are mutually exclusive, an increase in
one should be compensated by roughly equal decrease in the other
if all full length APP is cleaved, in similar proportions, by either a-
or b-secretase. However, we report a ,15-fold increase in soluble
sAPP-a but only a ,3.5 -fold decrease in sAPP-b. Unless in vivo
sAPP-b is cleared more efficiently than sAPP-a, these differences
are not consistent with the aforementioned model. A recent report
shows that APP is cleaved in the ectodomain buy an alternative,
albeit yet to be identified, protease [21]. In addition, a large
fraction of full length APP is processed by lysosomes, presumably
after APP is internalized [22] (Fig. 3B). The YG mutation could
reduce BACE and lysosomal degradation of APP, if mutant APP
has impaired endocytosis [both processes are largely dependent of
APP endocytosis [22,23,24]). This would also explain the vast
increase in a-secretase processing of the YG APP mutant. This
hypothesis is presently being investigated.
Also C83 and C99 undergo lysosomal degradation (Fig. 3B),
indicating that these APP metabolites are not exclusively cleaved
by g-secretase. Interestingly, inhibition of lysosomal degradation
results in the appearance of several COOH-terminal APP
fragments larger than C99 [see asterisks in Fig. 3B for both
primary neurons and primary mouse dermal fibroblasts (MDFs)].
These fragments are either intermediated of APP degradation in
lysosomes, or are produced by processing of APP in regions NH2-
terminal to the BACE1 cutting site, suggesting that the APP
ectodomain can be processed by several unknown proteases, in
addition to a- and b-secretase.
The decrease in Ab40 level (25%) is not as pronounced as the
reduction in sAPPb levels. This apparent discrepancy can be
explained by either reduced clearance of brain Ab, a compensa-
tory increase in c-cleavage of C99, or by reduced clearance of C99
by the lysosomes. These possibilities are being investigated.
As noted above, intracellular transport and localization of APP
are critical components of APP processing and Ab production. In
fact, a-secretase cleaves mAPP en route to or on the plasma
membrane. b-secretase predominantly cleaves mAPP in early
endosomes [23,24] while C99 and C83 are processed by the c-
secretase in endocytic compartments [24]. Thus, the shift toward
the non-amyloidogenic processing in APP
YG/YG mice may involve
a role of Tyr
682 in trafficking of APP along the secretory pathway.
However, the YG mutation neither altered the imAPP/mAPP
ratio in brains (Fig. 4A and B) and primary mouse dermal
fibroblasts (MDFs) (Fig. 4C), nor changed the levels of plasma
membrane mAPP in MDFs (Fig. 3C).
Normal brain organization and distributions of neural
proteins in APP
YG/YG mice
A number of studies suggest important neurological roles for
APP and APP polypeptides derived by secretases processing.
sAPP-a is neuro-protective [25,26,27,28]. A metabolite of sAPP-b
interacts with DR6 to trigger neuronal death [29]. Ab is critical for
LTP induction and memory acquisition [30]. AID/AICD
modulates cell death, gene transcription and Ca
++ homeostasis
[3,4,31,32,33,34,35,36,37,38,39,40]. Because APP derived poly-
peptides are significantly changed in APP
YG/YG mice, we analyzed
whether these mutant mice show abnormalities in brain
organization. First, a general histopathological examination of
the APP
YG/YG mouse showed the following. All mice had minimal
multifocal myofiber degeneration affecting the appendicular
musculature, primarily, the biceps femoris, quadriceps, and triceps
brachii muscles. Randomly scattered throughout the striated
muscles were small clusters of swollen muscle fibers with increased
cytoplasmic eosinophilia and occasional karyorrhexis (Figure 5).
These myofibers were surrounded by myocytes with variable cross
sectional diameter and occasional rowing of central nuclei
interpreted as myofiber regeneration.
Figure 3. Normal expression of the mutant APP allele. A, The genetic manipulation of the APP gene locus in APP
YG/YG mice does not affect
transcription/splicing of APP since mRNA APP levels are comparable to those transcribed in age-matched APP
WT/WT mice (analogous data were
obtained using Beta Actin as housekeeping gene). B, APP and APP-derived CTFs are processed by the lysosomes. Inhibition of lysosomal activity by
chloroquine (Chl.) results in accumulation of APP and APP derived fragments. The asterisks indicate APP-CTFs that are derived by cleavages in the
ectodomain NH2-terminal to the site processed by BACE1. The effectiveness of Chl. in inhibiting lysosomal degradation (inhibition occurs at 50 mM
concentration but not at 5 mM) is confirmed by the accumulation on LC3II [78]. The antibody against LC3 is from Cell Signaling.
doi:10.1371/journal.pone.0015503.g003
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following levels- olfactory bulbs, cerebral cortex, thalamus,
midbrain and medulla. Each of these regions was further serially
sectioned at 250-micron intervals and stained with H&E.
Histological examination revealed no structural or anatomical
differences between the APP
YG/YG and the wild type mice (Fig. 6).
Next, we tested distribution of neural proteins using a
biochemical approach. Recent evidence suggest a role for APP
in synaptic function and numerous data support a role for synaptic
dysfunction underlying subtle memory changes in AD [41]. Since
the presynaptic regions of neurons are thought to be the main
source of Ab in the brain, attention has been focused on axonal
APP trafficking. These studies have unveiled an active role for APP
in axonal transport. APP is transported anterogradely by
conventional kinesin in tubular vesicles [42,43,44,45,46,47,48].
Although a direct interaction of APP with the motor protein
kinesin-1 has been proposed [49], following studies have
contradicted this conclusion [50,51] and shown that APP interacts
with kinesin-1 trough the APP-interacting proteins JIP1, a c-Jun
N-terminal kinase JNK-signaling scaffold protein [51,52,53]. It has
also been proposed that b- (BACE1) and c-secretases transported
in APP-containing vesicles and that APP functions as a receptor
for the cargo transport [54]. A number of observations suggest that
microtubule-dependent axonal transport is impaired in AD
human brains [5,55,56,57,58] as well as APP transgenic mice
[5,59,60]. Because of the indication that the intracellular domain
of APP is important for axonal transport of APP and cargo
molecules, we analyzed the synaptic distribution of neural
proteins. We studied APP. BACE1, a component of the c-
secretase complex, Nicastrin, and synaptic proteins/receptors,
such as PSD95, SVP38, the Glutamate receptors NMDAR1,
NMDAR2A, NMDAR2B and GLuR2/3/4. The synaptic levels of
these proteins were unchanged (Fig. 7), further supporting the
notion that the YG mutation does not affect APP maturation and
trafficking and that APP may not be a regulator of fast anterograde
axonal transport.
Absence of APP/Fe65 interaction in APP Y682G mutant
mice
Several cytosolic proteins bind APP. These APP-interacting
proteins regulate both APP processing and functions of APP
polypeptides in vitro [51,52,53,61,62,63,64,65,66,67,68]. However,
the in vivo relevance of these findings is still unclear. Most of these
interactions involve the YENPTY sequence (amino acids 682–687)
of APP. Phosphorylation of APP is consequential. Some proteins
interact with APP only when Tyr
682 is phosphorylated
[14,69,70,71]; others, like Fe65, Fe65L1 and Fe65L2, only when
this tyrosine is not phosphorylated [13]. The same is true for
Figure 4. Maturation and membrane levels of APP are
unaffected by the YG mutation. A, Immunoblot analysis comparing
imAPP and mAPP between APP
wt/wt and APP
YG/YG mice (n=3). B,
Quantitative analysis of panel A shows no differences in mAPP and
imAPP levels between the two genotypes. C, Biotynilation experiment
in APP
wt/wt and APP
YG/YG MDFs shows comparable levels of im and
mAPP, as well as cell membrane levels of mAPP.
doi:10.1371/journal.pone.0015503.g004
Figure 5. Alterations in quadriceps muscle from two APP
YG/YG mice. A, normal striated muscle. B, muscle fibers undergoing regeneration.
doi:10.1371/journal.pone.0015503.g005
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668 [67,72]. These data suggest that phosphorylation–dephos-
phorylation on Tyr
682 and Thr
668 modulates APP interactions and
function. Notably, Tyr
682 and Thr
668 phosphorylation is increased
in AD brains [9,73]. The APP/Fe65 interaction is the best
characterized of many potential APP/APP C-terminal binding
protein complexes. In vitro studies have suggested a role for APP/
Fe65 complexes in APP metabolism, and for AID-AICD/Fe65 in
gene transcription [4,62,74]. Tyr
682 is essential for a robust APP/
Fe65 interaction to occur in vitro [75] and, as noted above, other in
vitro evidence shows that Tyr
682phosphorylation abolishes docking
of Fe65 to APP. To establish whether this important role of Tyr
682
is true in vivo co-IP of APP and Fe65 was carried out using brain
tissue from APP
YG/YG, APP
2/2 and APP
wt/wt control mice
(Fig. 8). Panel A shows co-IP using a-APP antibody. The loss of
detectable signal for Fe65 in both APP
2/2 and APP
YG/YG mice
compared to APP
wt/wt control clearly demonstrates that Tyr
682 is
specifically required for this interaction to occur. Conversely Panel
B shows an IP experiment using a-Fe65 antibody and clearly
shows an absence of binding of APP in APP
YG/YG mice,
again demonstrating the necessity of Tyr
682 in the APP/Fe65
interaction.
Discussion
Mis-folding of amyloidogenic Ab peptides, particularly Ab42, is
a key feature of the AD pathology. APP Y682G mutation in mice
clearly results in a large redistribution of APP towards non-
amyloidogenic pathway; sAPP-a and C83 are greatly increased
while sAPP-b and Ab40 are decreased (Fig. 2), thus demonstrating
the necessary role of the C-terminal in normal activity of the
amyloidogenic pathway in the brain and consistent with the results
observed in vitro. It is not yet apparent why a concurrent reduction
in C99 or p-C99 was not observed. It is interesting to speculate,
based upon previous findings, how this profound shift in APP
processing may influence physiology in APP
YG/YG mice. sAPP-a
for instance is a proposed growth factor with neuroprotective
properties, therefore the 15-fold over expression may result in
different growth characteristics and a resistance to stress, although
no differences in brain organization were apparent in our analysis
(Fig. 5, 6).
A possible mechanism to explain this shift toward the non-
amyloidogenic processing may involve the essential role of Tyr
682
for normal endocytosis of APP as previously shown in vitro [11]. A
fraction of APP is cleaved by a-secretase in a post-Golgi
compartment or at the plasma membrane. Alternatively, some
APP is processed by b-secretase in the Golgi or in late endosomes
following internalization from the cell membrane. In addition Ab
levels tightly correlate with APP internalization such that Ab
secretion is significantly decreased when APP endocytosis is
compromised in vitro [23,24]. However our initial analysis of APP
localization shows no difference in cell surface APP (Fig. 4C).
We also demonstrate that Tyr
682 is necessary for interaction
between APP and binding partner Fe65 in vivo (Fig. 8).
Interestingly Fe65 also plays role in endocytosis of APP. Fe65
simultaneously binds to the cytoplasmic tail of APP and of LRP1
into a trimeric complex [62,76,77]. This interaction results in
accelerated endocytosis of APP via clathrin-coated pits and in
delivery to late endosomal compartments for cleavage by b- and c-
secretase to generate Ab [72]. The decrease in amyloidogenic
processing in APP
YG/YG mice may be consistent with this data.
Another known function of the APP/Fe65 interaction, which
should be absent in APP
YG/YG mice, is the transcriptional activity
of AID/Fe65/Tip60 complex [4], although further investigation
will be needed to determine if this is true. Also of note is that
phosphorylation of Tyr
682 also disrupts interaction of APP with
Fe65 and other PTB domain proteins [13,14] and this may be one
commonality between APP
YG/YG mice and AD brain.
A comparative analysis between APP
YG/YG, APP
TA/TA and
control mice clearly indicates steady-state APP phosphorylation
predominantly occurs on Thr
668 and not Tyr
682 in normal brain
(Fig. 2D). Counter intuitively, this observation may exemplify the
importance of Tyr
682 phosphorylation. Evidence shows Tyr
682 is
hyperphosphorylated in the AD Brain [9,10]. It is plausible that
excessive phosphorylation at this functionally important residue
could lead to toxic effects, given its relative scarcity under normal
conditions. For example, if Tyr
682 phosphorylation plays a role in
targeting APP for degradation via secretase, lysosomal or
Figure 6. Coronal sections comparing brain anatomy of
APP
wt/wt with APP
YG/YG mice. A–E coronal sections of APP
wt/wt
mouse, F–J coronal sections of APP
YG/YGmouse. A, F - Olfactory bulbs.
B, G- Cerebral cortex. C, H- Thalamus. D, I- Midbrain. E, J- Medulla. Ob-
olfactory bulb, r-retina, cc- cerebral cortex, s- striatum, hi- hippocampus,
th- thalamus, mb- midbrain, ce- cerebellum.
doi:10.1371/journal.pone.0015503.g006
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APP and pY682-APP-CTFs proteins would be very difficult in a
normal brain.
Given the functional redundancy provided by APLP1 and APLP2
much of the phenotype in APP
YG/YG mice is potentially masked.
Therefore a very important goal is to cross APP
YG/YG mice with
APLP2
2/2 mice. If significant APP functionality is facilitated by
Tyr
682 then we may see aspects of the severe APP
2/2/APLP2
2/2
mice phenotype reproduced in a context that allows a much more
detailed picture of APP function to be dissected. Physiological
characterization of this model in addition to APP
YG/YG mice is
therefore of great interest.
In summary, we have successfully generated two APP KI mouse
lines, APP Y682G & T668A, and carried out an initial
characterization focusing on APP Y682G. Both APP processing
and the APP/Fe65 interaction are significantly altered as a result
of this mutation, in agreement with previous in vitro studies. In
addition these findings have a therapeutic implication, demon-
strating that manipulation of this amino acid could increase
production of the sAPPa, considered a protective protein, and
decrease the generation of toxic fragments such as Ab40 & 42.
without negative physiological consequences. Overall, the data
suggests a very important in vivo role for Tyr
682 in the brain.
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